NKTX IPOs 16.1M* shares @$18.00: https://www.globenewswire.com/news-release/2020/07/10/2060366/0/en/Nkarta-Announces-Pricing-of-Initial-Public-Offering.html Nkarta, Inc. focuses on combining its natural killer (NK) cell expansion and cryopreservation platform with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. Nkarta’s mission is to discover, develop and deliver novel off-the-shelf NK cell therapy product candidates that have a profound impact on patients. *Assuming exercise of underwriter’s option.